Clovis gets European regulatory OK for its ovarian cancer drug

Clovis Oncology Inc. said it's received approval from the European Commission for its drug to treat recurrent ovarian cancer in women. The Boulder biotech (Nasdaq: CLVS) said the European regulators okayed its Rubraca (rucaparib) drug treatment for women with BRCA mutated ovarian cancer. The company, and its CEO Patrick Mahaffy, were profiled by the Denver Business Journal's Greg Avery last month, including the company's plans f or the drug in the U.S. "The granting of the (European) license means…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Source Type: news